IL284156B2 - Anti-CTLA–4 binding proteins and methods of using them - Google Patents
Anti-CTLA–4 binding proteins and methods of using themInfo
- Publication number
- IL284156B2 IL284156B2 IL284156A IL28415621A IL284156B2 IL 284156 B2 IL284156 B2 IL 284156B2 IL 284156 A IL284156 A IL 284156A IL 28415621 A IL28415621 A IL 28415621A IL 284156 B2 IL284156 B2 IL 284156B2
- Authority
- IL
- Israel
- Prior art keywords
- seq
- antibody
- ctla
- cdr1
- cdr2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785659P | 2018-12-27 | 2018-12-27 | |
| PCT/US2019/068820 WO2020140084A1 (en) | 2018-12-27 | 2019-12-27 | Anti-ctla-4 binding proteins and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL284156A IL284156A (en) | 2021-08-31 |
| IL284156B1 IL284156B1 (en) | 2024-12-01 |
| IL284156B2 true IL284156B2 (en) | 2025-04-01 |
Family
ID=71126610
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL284156A IL284156B2 (en) | 2018-12-27 | 2019-12-27 | Anti-CTLA–4 binding proteins and methods of using them |
| IL316757A IL316757A (en) | 2018-12-27 | 2019-12-27 | Anti-CTLA-4 binding proteins and methods of using them |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL316757A IL316757A (en) | 2018-12-27 | 2019-12-27 | Anti-CTLA-4 binding proteins and methods of using them |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12421311B2 (https=) |
| EP (1) | EP3902821A4 (https=) |
| JP (2) | JP7558949B2 (https=) |
| KR (1) | KR20210121045A (https=) |
| CN (2) | CN119930820A (https=) |
| AU (2) | AU2019413366B2 (https=) |
| BR (1) | BR112021012588A2 (https=) |
| CA (2) | CA3124961C (https=) |
| IL (2) | IL284156B2 (https=) |
| MX (1) | MX2021007848A (https=) |
| SG (1) | SG11202106764YA (https=) |
| WO (1) | WO2020140084A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3002957A1 (en) * | 2015-10-23 | 2017-04-27 | Koninklijke Nederlandse Akademie Van Wetenschappen | Binding molecules that inhibit cancer growth |
| AU2019413366B2 (en) | 2018-12-27 | 2025-06-05 | Gigagen, Inc. | Anti-CTLA-4 binding proteins and methods of use thereof |
| CA3184082A1 (en) * | 2020-07-02 | 2022-01-06 | David Scott Johnson | Anti-ctla-4 binding proteins and methods of use thereof |
| JP2024502035A (ja) * | 2020-12-31 | 2024-01-17 | ノヴァロック バイオセラピューティクス， リミテッド | Ｔｎｆｒ２に対する抗体およびそれの使用 |
| WO2023279068A1 (en) * | 2021-07-02 | 2023-01-05 | Gigagen, Inc. | Anti-ctla-4 binding proteins and methods of use thereof |
| AU2022407541A1 (en) * | 2021-12-10 | 2024-06-13 | Merck Sharp & Dohme Llc | Human mesothelin binders |
| WO2023215560A1 (en) | 2022-05-05 | 2023-11-09 | Atoosa Corporation | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL148079A0 (en) * | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US20110166335A1 (en) | 2000-06-30 | 2011-07-07 | Corbin David R | Xenorhabdus sp. genome sequences and uses thereof |
| TWI320716B (en) * | 2002-10-14 | 2010-02-21 | Abbott Lab | Erythropoietin receptor binding antibodies |
| US20090252741A1 (en) | 2004-09-08 | 2009-10-08 | Ohio State University Research Foundation | Human monoclonal anti-ctla4 antibodies in cancer treatment |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| CN104968364A (zh) | 2012-12-03 | 2015-10-07 | 百时美施贵宝公司 | 强化免疫调变性Fc融合蛋白的抗癌活性 |
| WO2015092394A1 (en) | 2013-12-17 | 2015-06-25 | Kymab Limited | Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations |
| PT3151921T (pt) * | 2014-06-06 | 2019-11-21 | Bristol Myers Squibb Co | Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos |
| CN108271359B (zh) * | 2015-02-13 | 2021-11-09 | 索伦托药业有限公司 | 结合ctla4的抗体治疗剂 |
| TN2017000440A1 (en) | 2015-04-17 | 2019-04-12 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| MA44594B1 (fr) * | 2015-05-29 | 2020-09-30 | Memorial Sloan Kettering Cancer Center | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci |
| FI3389699T3 (fi) | 2015-12-15 | 2024-05-28 | Oncoc4 Inc | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja |
| SG10201603721TA (en) * | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
| CN120173123A (zh) | 2017-02-27 | 2025-06-20 | 蜻蜓疗法股份有限公司 | 靶向caix、ano1、间皮素、trop2、cea或紧密连接蛋白-18.2的多特异性结合蛋白 |
| US11643463B2 (en) * | 2017-05-19 | 2023-05-09 | Wuxi Biologics (Shanghai) Co., Ltd. | Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) |
| TWI799432B (zh) | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| AU2019413366B2 (en) | 2018-12-27 | 2025-06-05 | Gigagen, Inc. | Anti-CTLA-4 binding proteins and methods of use thereof |
| EP3914355A1 (en) | 2019-01-21 | 2021-12-01 | Sanofi | Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers |
| CA3184082A1 (en) | 2020-07-02 | 2022-01-06 | David Scott Johnson | Anti-ctla-4 binding proteins and methods of use thereof |
-
2019
- 2019-12-27 AU AU2019413366A patent/AU2019413366B2/en active Active
- 2019-12-27 IL IL284156A patent/IL284156B2/en unknown
- 2019-12-27 CA CA3124961A patent/CA3124961C/en active Active
- 2019-12-27 US US17/418,776 patent/US12421311B2/en active Active
- 2019-12-27 IL IL316757A patent/IL316757A/en unknown
- 2019-12-27 SG SG11202106764YA patent/SG11202106764YA/en unknown
- 2019-12-27 KR KR1020217023740A patent/KR20210121045A/ko active Pending
- 2019-12-27 BR BR112021012588-4A patent/BR112021012588A2/pt unknown
- 2019-12-27 WO PCT/US2019/068820 patent/WO2020140084A1/en not_active Ceased
- 2019-12-27 EP EP19902920.8A patent/EP3902821A4/en active Pending
- 2019-12-27 CN CN202510014877.4A patent/CN119930820A/zh active Pending
- 2019-12-27 JP JP2021537082A patent/JP7558949B2/ja active Active
- 2019-12-27 MX MX2021007848A patent/MX2021007848A/es unknown
- 2019-12-27 CA CA3249127A patent/CA3249127A1/en active Pending
- 2019-12-27 CN CN201980092796.9A patent/CN114008071B/zh active Active
-
2024
- 2024-02-02 JP JP2024014900A patent/JP7745669B2/ja active Active
-
2025
- 2025-08-27 AU AU2025223772A patent/AU2025223772A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7558949B2 (ja) | 2024-10-01 |
| JP2022516071A (ja) | 2022-02-24 |
| AU2019413366A1 (en) | 2021-08-12 |
| IL284156B1 (en) | 2024-12-01 |
| WO2020140084A1 (en) | 2020-07-02 |
| IL316757A (en) | 2025-01-01 |
| IL284156A (en) | 2021-08-31 |
| AU2019413366B2 (en) | 2025-06-05 |
| MX2021007848A (es) | 2021-10-26 |
| US20220064303A1 (en) | 2022-03-03 |
| JP7745669B2 (ja) | 2025-09-29 |
| CN114008071A (zh) | 2022-02-01 |
| AU2025223772A1 (en) | 2025-09-18 |
| KR20210121045A (ko) | 2021-10-07 |
| CA3124961C (en) | 2025-11-25 |
| EP3902821A4 (en) | 2022-11-30 |
| JP2025128343A (ja) | 2025-09-02 |
| EP3902821A1 (en) | 2021-11-03 |
| CN119930820A (zh) | 2025-05-06 |
| US12421311B2 (en) | 2025-09-23 |
| BR112021012588A2 (pt) | 2021-09-08 |
| SG11202106764YA (en) | 2021-07-29 |
| CN114008071B (zh) | 2025-01-21 |
| CA3249127A1 (en) | 2026-03-02 |
| CA3124961A1 (en) | 2020-07-02 |
| JP2024042072A (ja) | 2024-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3124961C (en) | ANTI-CTLA-4 BINDING PROTEINS AND METHODS OF USING THEM | |
| US20220064302A1 (en) | Anti-PD-1 Binding Proteins and Methods of Use Thereof | |
| WO2020140094A1 (en) | Anti-b7-h3 binding proteins and methods of use thereof | |
| US20230265192A1 (en) | Anti-ctla-4 binding proteins and methods of use thereof | |
| WO2020142626A1 (en) | Anti-ox40 binding proteins and methods of use thereof | |
| WO2022006555A2 (en) | BISPECIFIC ANTIGEN BINDING PROTEINS TARGETING PD-L1 AND TGF-β AND METHODS OF USE | |
| US20220056137A1 (en) | Anti-PD-L1 Binding Proteins and Methods of Use Thereof | |
| WO2020140070A1 (en) | Anti-b7-h4 binding proteins and methods of use thereof | |
| JP7854093B2 (ja) | 抗ｃｔｌａ－４結合タンパク質およびその使用方法 |